Paola Martinez

Paola Martinez

Auto-generated profile, based on publicly available information

Paola Martinez

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Immunity
Verified
Journal Article
Closed access
PMPaola Martinez-Murillo
Paola Martinez-Murillo
KTKaren Tran
Karen Tran
JGJavier Guenaga
Javier Guenaga
GLGustaf Lindgren
Gustaf Lindgren
MÀMonika Àdori
Monika Àdori
GHGunilla Karlsson Hedestam
Gunilla Karlsson Hedestam

15 June 2015 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
GPGanesh E Phad
Ganesh E Phad
NBNéstor Vázquez Bernat
Néstor Vázquez Bernat
YFYu Feng
Yu Feng
JIJidnyasa Ingale
Jidnyasa Ingale
PMPaola Andrea Martinez Murillo
Paola Andrea Martinez Murillo
GHGunilla Karlsson Hedestam
Gunilla Karlsson Hedestam
Isolation of mAbs elicited by vaccination provides opportunities to define the development of effective immunity. Ab responses elicited by current HIV-1 envelope glycoprotein (Env) immunogens display narrow neutralizing activity with limited capacity to block infection by tier 2 viruses. Intense work in the field suggests that improved Env immunogens are forthcoming, and it is therefore important to concurrently develop approaches to investigate the quality of vaccine-elicited responses at a higher level of resolution. In this study, we cloned a representative set of mAbs elicited by a model Env immunogen in rhesus macaques and comprehensively characterized their genetic and functional properties. The mAbs were genetically diverse, even within groups of Abs targeting the same subregion of Env, consistent with a highly polyclonal response. mAbs directed against two subdeterminants of Env, the CD4 binding site and V region 3, could in part account for the neutralizing activity observed in the plasma of the animal from which they were cloned, demonstrating the power of mAb isolation for a detailed understanding of the elicited response. Finally, through comparative analyses of mAb binding and neutralizing capacity of HIV-1 using matched Envs, we demonstrate complex relationships between epitope recognition and accessibility, highlighting the protective quaternary packing of the HIV-1 spike relative to vaccine-induced mAbs.

27 June 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
PMPaola Martinez-Murillo
Paola Martinez-Murillo
LPLotta Pramanik
Lotta Pramanik
CSChristopher Sundling
Christopher Sundling
KHKjell Hultenby
Kjell Hultenby
PWPer Wretenberg
Per Wretenberg
GHGunilla Karlsson Hedestam
Gunilla Karlsson Hedestam
Plasma cells (PCs) are defined as terminally differentiated B cells that secrete large amounts of immunoglobulin (Ig). Plasma cells that reside in the bone marrow (BM) are responsible for maintaining long-term antibody responses after infection and vaccination, while plasma cells present in the blood are generally short-lived. In rhesus macaques, a species frequently used for the evaluation of human vaccines, B cells resemble those found in humans. However, a detailed characterization of BM-resident rhesus plasma cell phenotype and function is lacking. Here, we examined Ig secretion of distinct rhesus CD138+ populations by B cell ELISpot analysis to couple phenotype with function. We demonstrate that the CD20low/-CD138+CD31+ BM population was highly enriched for antibody-secreting cells with IgG being the predominant isotype (60%), followed by IgA (33%) and IgM (7%). Transmission electron microscopy (TEM) analysis confirmed plasma cell enrichment in the CD20low/-CD138+CD31+ population with cells containing nuclei with “spokes of a wheel” chromatin structure and prominent rough endoplasmic reticulum. This panel also stained human BM PCs and allowed a clear distinction between BM PCs and short-lived peripheral plasma cells, providing an improved strategy to isolate PCs from rhesus bone marrow for further analysis.

8 November 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
GPGanesh E. Phad
Ganesh E. Phad
PPPradeepa Pushparaj
Pradeepa Pushparaj
KTKaren Tran
Karen Tran
VDViktoriya Dubrovskaya
Viktoriya Dubrovskaya
MÀMonika Àdori
Monika Àdori
GHGunilla Karlsson Hedestam
Gunilla Karlsson Hedestam
Well-ordered HIV-1 envelope glycoprotein (Env) trimers are prioritized for clinical evaluation, and there is a need for an improved understanding about how elicited B cell responses evolve following immunization. To accomplish this, we prime-boosted rhesus macaques with clade C NFL trimers and identified 180 unique Ab lineages from ∼1,000 single-sorted Env-specific memory B cells. We traced all lineages in high-throughput heavy chain (HC) repertoire (Rep-seq) data generated from multiple immune compartments and time points and expressed several as monoclonal Abs (mAbs). Our results revealed broad dissemination and high levels of somatic hypermutation (SHM) of most lineages, including tier 2 virus neutralizing lineages, following boosting. SHM was highest in the Ab complementarity determining regions (CDRs) but also surprisingly high in the framework regions (FRs), especially FR3. Our results demonstrate the capacity of the immune system to affinity-mature large numbers of Env-specific B cell lineages simultaneously, supporting the use of regimens consisting of repeated boosts to improve each Ab, even those belonging to less expanded lineages.

16 November 2012 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
CSChristopher Sundling
Christopher Sundling
PMPaola Martinez
Paola Martinez
MSMartina Soldemo
Martina Soldemo
MSMats Spångberg
Mats Spångberg
KBKarin Lövgren Bengtsson
Karin Lövgren Bengtsson
GHGunilla Karlsson Hedestam
Gunilla Karlsson Hedestam
The envelope glycoproteins (Env) represent a critical component of a successful antibody-mediated human immunodeficiency virus type 1 (HIV-1) vaccine. However, immunization with soluble Env was reported to induce short-lived antibody responses, suggesting that Env has unusual immunogenic properties. Here, we directly compared the magnitude and durability of B-cell responses induced by HIV-1 Env and an unrelated soluble viral protein, influenza virus hemagglutinin (HA), in simultaneously inoculated macaques. We demonstrate robust peak responses followed by rapid contraction of circulating antibody and memory B cells for both antigens, suggesting that short-lived responses are not unique to HIV-1 Env but may be a common feature of soluble protein vaccines.

12 March 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PMPaola Martinez
Paola Martinez
CSChristopher Sundling
Christopher Sundling
SOSijy O'DEll
Sijy O'DEll
JMJohn R. Mascola
John R. Mascola
RWRichard T. Wyatt
Richard T. Wyatt
GHGunilla Karlsson Hedestam
Gunilla Karlsson Hedestam
Protein-based vaccines require adjuvants to achieve optimal responses. Toll-like receptor (TLR) 9 agonists were previously shown to improve responses to protein-based vaccines, such as the Hepatitis B virus vaccine formulated in alum. Here, we used CpG-C together with the clinically relevant saponin-based adjuvant AbISCO-100/Matrix-M (AbISCO), to assess if TLR9 co-stimulation would quantitatively or qualitatively modulate HIV-1 envelope glycoprotein (Env)-specific B and T cell responses in rhesus macaques. The macaques were inoculated with soluble Env trimers in AbISCO, with or without the addition of CpG-C, using an interval similar to the Hepatitis B virus vaccine. Following a comprehensive evaluation of antigen-specific responses in multiple immune compartments, we show that the Env-specific circulating IgG, memory B cells and plasma cells displayed similar kinetics and magnitude in the presence or absence of CpG-C and that there was no apparent difference between the two groups in the elicited HIV-1 neutralizing antibody titers or antigen-specific CD4+ T cell responses. Importantly, the control of SHIV viremia was significantly improved in animals from both Env-immunized groups relative to adjuvant alone controls, demonstrating the potential of AbISCO to act as a stand-alone adjuvant for Env-based vaccines.